ctDNA Improves Prognostic Prediction for Patients with Relapsed/Refractory MM Receiving Ixazomib, Lenalidomide, and Dexamethasone

The authors performed targeted-capture sequencing using bone marrow plasma cells and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, and dexamethasone in a multicenter, prospective, observational study.